Ed Mahon | Spotlight PA

With millions of dollars at stake, certification businesses buy radio ads, dominate Google searches, and even offer Groupons. But if doctors do the same, they risk their license.

Only a few dozen addiction recovery homes in Pennsylvania have applied for a license despite the licensing program being designed to bring more oversight to the critical industry.

The leader of a state agency that failed to clarify rules around addiction treatment and medical marijuana — an action that had serious consequences — continued to deny blame while speaking before state lawmakers this month.

Experts and advocates fear the decline in Child Care Works enrollment is a sign the pandemic has forced low-income families to prioritize home care over earning a paycheck.

As part of a first-of-its-kind review, Spotlight PA investigated claims made on Pennsylvania cannabis companies’ websites and found a wide range of misleading tactics.

A letter from the Department of Justice could have widespread ramifications for Pennsylvanians who are under a court’s supervision and use doctor-prescribed medications to treat opioid use disorder.

The shortages, caused by low wages and razor-thin profit margins, have ripple effects that reach far beyond the classroom and affect everyone.

The Wolf administration could implement new oversight of recovery homes by mid-2022, though challenges could cause delays.

For 17 months, medical marijuana users were wrongly denied access to some care and funding options because of the Wolf administration’s inaction.

The Office of Open Records ruled in favor of Spotlight PA and ordered the health department to disclose how many patients are certified for cannabis under each of the state’s qualifying conditions.